Fineline Cube

Follow:
14398 Articles
Teva Pharmaceutical Reaches Settlement with DOJ Over Alleged Kickbacks and Price-Fixing
Company

Teva Pharmaceutical Reaches Settlement with DOJ Over Alleged Kickbacks and Price-Fixing

CSPC Pharma Initiates Phase III Trial for JMT101 in First-Line EGFR-Positive NSCLC Treatment
CompanyDrug

CSPC Pharma Initiates Phase III Trial for JMT101 in First-Line EGFR-Positive NSCLC Treatment

KangaBio's KGX101 Receives NMPA Approval for Clinical Trial in China
CompanyDrug

KangaBio’s KGX101 Receives NMPA Approval for Clinical Trial in China

Johnson & Johnson’s KLK2-CD3 Bispecific Antibody JNJ-78278343 Advances in Prostate Cancer Clinical Trials
Drug

Johnson & Johnson’s KLK2-CD3 Bispecific Antibody JNJ-78278343 Advances in Prostate Cancer Clinical Trials

Merck KGaA’s Pergoveris Treatment Expands Access to Advanced Reproductive Care in Greater Bay Area
CompanyDrug

Merck KGaA’s Pergoveris Treatment Expands Access to Advanced Reproductive Care in Greater Bay Area

Junshi Biosciences' Ongericimab Wins NMPA Nod for Hypercholesterolemia Treatment
CompanyDrug

Junshi Biosciences’ Ongericimab Wins NMPA Nod for Hypercholesterolemia Treatment

WuXi AppTec Addresses Media Speculation on Potential Sale of WuXi ATU
Company

WuXi AppTec Addresses Media Speculation on Potential Sale of WuXi ATU

Juventas Cell Therapy's CAR-T Therapy Clears for SLE-ITP Study in China
CompanyDrug

Juventas Cell Therapy’s CAR-T Therapy Clears for SLE-ITP Study in China

Sanofi Commences Negotiations with CD&R for Potential Sale of Opella Stake
CompanyDeals

Sanofi Commences Negotiations with CD&R for Potential Sale of Opella Stake

SAMR Proposes Guidelines to Curb Commercial Bribery in Pharmaceutical Industry
Policy / Regulatory

SAMR Proposes Guidelines to Curb Commercial Bribery in Pharmaceutical Industry

JD Healthcare and Genrix Bio Join Forces to Revolutionize Patient Care and Pharmacy Services
CompanyDeals

JD Healthcare and Genrix Bio Join Forces to Revolutionize Patient Care and Pharmacy Services

Guangdong Province Aims for RMB One Trillion in Biopharma Industry Growth by 2027
Policy / Regulatory

Guangdong Province Aims for RMB One Trillion in Biopharma Industry Growth by 2027